Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.4% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
13
users have liked this narrative
8
users have commented on this narrative
50
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
24.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.4% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Village Farms International
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Regulatory Hurdles In Germany Will Pressure Margins Though Gains Beckon
Key Takeaways Broad international expansion and regulatory shifts are driving growth but expose the company to pricing pressure, margin volatility, and operational complexity risks. Investments in cannabis cultivation and efficiency gains may be negated by stricter environmental regulations, rising compliance costs, and competitive threats from alternative production methods.
View narrative
US$3.25
FV
10.8% undervalued
intrinsic discount
-4.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Karyopharm Therapeutics
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Liquidity Strains And Overreliance Will Mar Outlook But Support Recovery
Key Takeaways Heavy reliance on a single drug and looming debt maturity create significant operational and financial vulnerability amid intensifying industry competition. Regulatory constraints, limited resources, and weak partnerships threaten pricing power, expansion efforts, and long-term growth prospects.
View narrative
US$8.00
FV
30.1% undervalued
intrinsic discount
17.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
OptimizeRx
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Heightened Data Privacy And Provider Skepticism Will Hinder Healthcare Transformation
Key Takeaways Heightened regulatory scrutiny and data privacy restrictions threaten platform effectiveness, increase compliance costs, and limit future growth prospects. Declining provider engagement and digital tool commoditization risk compressing margins, while concentrated revenue sources heighten vulnerability to client loss.
View narrative
US$11.00
FV
54.4% overvalued
intrinsic discount
7.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
GrowGeneration
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
US Cannabis Regulations And Retail Shifts Will Limit Prospects
Key Takeaways Regulatory uncertainty and stricter environmental policies threaten to reduce demand for GrowGeneration's core products, heightening revenue and earnings risks. Shifts toward e-commerce, commoditization, and industry consolidation put pressure on margins and erode the company's competitive advantage in retail specialty supplies.
View narrative
US$1.50
FV
4.7% overvalued
intrinsic discount
-6.02%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Creo Medical Group
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Hospital Budget Pressures And Slow Adoption Will Limit Gains Slightly
Key Takeaways Adoption of Creo's technology faces hurdles from slow hospital procurement, budget pressures, and delayed integration of clinical evidence, restricting near-term revenue growth. Expansion is challenged by geopolitical risks, competitive medtech landscape, and potential margin pressures from ongoing high R&D spend and formidable incumbents.
View narrative
UK£0.40
FV
65.3% undervalued
intrinsic discount
64.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Outset Medical
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Aging Demographics Will Drive Tablo Home Dialysis Adoption
Key Takeaways Rapid adoption of Tablo and strategic partnerships position Outset Medical for faster recurring revenue growth, accelerating market share gains and long-term profitability. Demographic trends and expanding home care markets offer lasting tailwinds, boosting recurring revenue potential and reinforcing Outset Medical's status as a leading dialysis innovator.
View narrative
US$39.00
FV
64.9% undervalued
intrinsic discount
13.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Beachbody Company
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Digital Retail And Health Trends Will Unlock New Demand
Key Takeaways Shift from MLM to omnichannel retail and digital integration positions Beachbody for strong revenue growth and high customer engagement across brands and channels. Operational efficiencies and tech-driven personalization boost margins, customer retention, and recurring digital subscription revenue, outpacing market expectations.
View narrative
US$13.00
FV
56.5% undervalued
intrinsic discount
-17.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
CareCloud
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
AI And Integrated Cloud Solutions Will Reshape Care Delivery
Key Takeaways Accelerating adoption of CareCloud's AI-driven, cloud-based solutions and expansion into new markets are driving higher-than-expected, sustainable revenue and margin growth. Proprietary data assets and first-mover advantage enable competitive differentiation, recurring high-margin SaaS revenue, and potential for new business lines through advanced AI-powered offerings.
View narrative
US$6.00
FV
54.7% undervalued
intrinsic discount
6.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Modulight Oyj
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Laser Therapies Will Expand Precision Care For Aging Global Markets
Key Takeaways Expanded therapy indications, unique integration, and U.S. expansion could enable outsized market share capture and accelerate recurring revenue growth. Strategic partnerships and proprietary AI-driven devices position Modulight for premium pricing, income diversification, and sustained margin expansion.
View narrative
€2.20
FV
43.6% undervalued
intrinsic discount
41.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies